Crossref
IGHV mutational status and the choice of first-line therapy for patients with chronic lymphocytic leukaemia
Hematology in Clinical Practice · 2022
DOI: 10.5603/hcp.2022.0003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematology in Clinical Practice, 2022. Verfasst von Bartosz Puła und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Puła, B., Jamroziak, K., Wróbel, T., Giannopoulos, K., & Hus, I. (2022). IGHV mutational status and the choice of first-line therapy for patients with chronic lymphocytic leukaemia. Hematology in Clinical Practice. https://doi.org/10.5603/hcp.2022.0003
Vancouver
Puła B, Jamroziak K, Wróbel T, Giannopoulos K, Hus I. IGHV mutational status and the choice of first-line therapy for patients with chronic lymphocytic leukaemia. Hematology in Clinical Practice. 2022. doi:10.5603/hcp.2022.0003
BibTeX
@article{Pua2022,
author = {Puła, Bartosz and Jamroziak, Krzysztof and Wróbel, Tomasz and Giannopoulos, Krzysztof and Hus, Iwona},
title = {IGHV mutational status and the choice of first-line therapy for patients with chronic lymphocytic leukaemia},
journal = {Hematology in Clinical Practice},
year = {2022},
doi = {10.5603/hcp.2022.0003}
}
EUVIMED